These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 20394490)

  • 21. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis.
    Ingram JR; Martin JA; Finlay AY
    Am J Clin Dermatol; 2009; 10(4):229-37. PubMed ID: 19489656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis.
    Yin ZQ; Zhang WM; Song GX; Luo D
    J Dermatol; 2012 Jun; 39(6):520-6. PubMed ID: 22409418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis.
    Fleischer AB; Abramovits W; Breneman D; Jaracz E;
    J Dermatolog Treat; 2007; 18(3):151-7. PubMed ID: 17538803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
    Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
    J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
    Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
    J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
    Yang LP; Curran MP
    Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
    Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
    J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
    Remitz A; Harper J; Rustin M; Goldschmidt WF; Palatsi R; van der Valk PG; Sharpe G; Smith CH; Dobozy A; Turjanmaa K;
    Acta Derm Venereol; 2007; 87(1):54-61. PubMed ID: 17225017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
    Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
    Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis.
    Chapman MS; Schachner LA; Breneman D; Boguniewicz M; Gold MH; Shull T; Linowski GJ; Jaracz E;
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S177-85. PubMed ID: 16021173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.
    Ho VC; Gupta A; Kaufmann R; Todd G; Vanaclocha F; Takaoka R; Fölster-Holst R; Potter P; Marshall K; Thurston M; Bush C; Cherill R
    J Pediatr; 2003 Feb; 142(2):155-62. PubMed ID: 12584537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
    Doss N; Kamoun MR; Dubertret L; Cambazard F; Remitz A; Lahfa M; de Prost Y
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):321-9. PubMed ID: 19563466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.
    Kaufmann R; Bieber T; Helgesen AL; Andersen BL; Luger T; Poulin Y; Al-Hafidh J; Paul C;
    Allergy; 2006 Mar; 61(3):375-81. PubMed ID: 16436149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
    Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
    Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus ointment: new preparation. Too many unknowns.
    Prescrire Int; 2004 Jun; 13(71):86-9. PubMed ID: 15233141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
    Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
    Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.
    Hanifin JM; Paller AS; Eichenfield L; Clark RA; Korman N; Weinstein G; Caro I; Jaracz E; Rico MJ;
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 2):S186-94. PubMed ID: 16021174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.